Enliven Therapeutics (ELVN) Retained Earnings (2019 - 2026)
Enliven Therapeutics (ELVN) reported Retained Earnings of -$370.8 million for Q1 2026, down 36.32% on a YoY basis from -$582.3 million in Q1 2025, and down 111115.87% sequentially from $334000.0 in Q4 2025.
Enliven Therapeutics (ELVN) Retained Earnings (2019 - 2026) Analysis & Trends
Enliven Therapeutics (ELVN) has 8 years of Retained Earnings data on file, last reported at -$370.8 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 36.32% year-over-year to -$370.8 million; the trailing twelve-month figure through Mar 2026 stood at -$370.8 million (down 36.32% YoY), and the FY2025 full-year result was $334000.0, up 100.14% from the prior year.
- Retained Earnings slipped to -$370.8 million in Q1 2026, from $334000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $502.2 million in Q2 2024 to a low of -$370.8 million in Q1 2026.
- A 5-year average of -$60.3 million and a median of -$97.6 million in 2023 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings plunged 16213700.0% in 2022 and jumped 452496.4% in 2024, its largest moves.
- Tracing ELVN's Retained Earnings over 5 years: stood at $6.0 million in 2022, then soared by 6527.56% to $400.2 million in 2023, then slumped by 160.84% to -$243.5 million in 2024, then jumped by 100.14% to $334000.0 in 2025, then slumped by 111115.87% to -$370.8 million in 2026.
- Business Quant data shows ELVN's Retained Earnings at -$370.8 million in Q1 2026, $334000.0 in Q4 2025, and $221000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Enliven Therapeutics | 3.22 Bn | 3.22 Bn | - | -370.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -370.79 Mn |
| Dec 31, 2025 | 334,000.00 |
| Sep 30, 2025 | 221,000.00 |
| Jun 30, 2025 | -297.40 Mn |
| Mar 31, 2025 | -272.00 Mn |
| Dec 31, 2024 | -243.47 Mn |
| Sep 30, 2024 | 242,000.00 |
| Jun 30, 2024 | 502.16 Mn |
| Mar 31, 2024 | -177.19 Mn |
| Dec 31, 2023 | 400.17 Mn |
| Sep 30, 2023 | -135.08 Mn |
| Jun 30, 2023 | -111,000.00 |
| Mar 31, 2023 | -97.60 Mn |
| Dec 31, 2022 | 6.04 Mn |
| Sep 30, 2022 | -178.19 Mn |
| Jun 30, 2022 | -35,000.00 |
| Mar 31, 2022 | -162.14 Mn |
| Dec 31, 2021 | -147.50 Mn |
| Sep 30, 2021 | -133.20 Mn |
| Jun 30, 2021 | -119.50 Mn |